Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Lysis Buffer for Reliable Mouse Genotyping
2026-08-17
A scientifically grounded guide to using lysis buffer as a rapid genotyping kit component for mouse tissue. It connects pre-analytical DNA quality and genotype assignment with the interpretation of sophisticated cancer-model studies, while clearly separating validated evidence from translational assumptions.
-
ARCA EGFP mRNA for LNP Transfection Workflows
2026-08-17
ARCA EGFP mRNA provides a fast, direct fluorescence readout for comparing mRNA delivery, formulation toxicity, and mammalian cell gene expression. This workflow translates lessons from a GA/PPC-modified lipid nanoparticle study into practical assay controls without confusing reporter expression with therapeutic efficacy.
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-08-16
A 2025 study found that naturally occurring angiotensin peptide fragments can selectively enhance SARS-CoV-2 spike protein binding to AXL, ACE2, and neuropilin-1. Its peptide-truncation and tyrosine-modification experiments identify sequence features that may connect renin-angiotensin biology with viral receptor engagement, while also showing why binding assays should not be equated with infection outcomes.
-
Novel Allosteric PDK4 Inhibitors for Metabolic Disease
2026-08-15
Lee and colleagues used anthraquinone-based structural optimization to discover compound 8c, a potent allosteric pyruvate dehydrogenase kinase 4 (PDK4) inhibitor with activity in biochemical, metabolic, allergic, and cancer-related models. The study combines medicinal chemistry, pharmacokinetic assessment, molecular docking, and disease-relevant experiments to support the lipoamide-binding site as a tractable design region, while leaving important questions about selectivity, long-term safety, and clinical translation unresolved.
-
SLC2A5 Fructose Metabolism in PCNSL
2026-08-14
This Advanced Science study uses single-cell RNA and B-cell receptor profiling to show how glucose-poor, hypoxic conditions in primary central nervous system lymphoma reshape tumor and immune-cell metabolism. Functional testing identifies SLC2A5-dependent fructose uptake in lymphoma cells and tumor-supportive macrophages as a potential metabolic vulnerability linked to impaired T-cell function.
-
Potassium Iodide in Thyroid Research Workflows
2026-08-14
Potassium Iodide offers a practical, water-compatible iodide source for thyroid uptake, hormone synthesis, and protection-model research. This guide also clarifies how KI can be used alongside, but should not be confused with, the MMP-2-responsive immunotherapy platform reported in breast cancer research.
-
PNU 74654: Rethinking Wnt Pathway Translation
2026-08-13
A translational framework for using PNU 74654 to interrogate Wnt/β-catenin biology across cancer, stem cell, and progenitor-cell models without confusing pathway engagement with therapeutic validation.
-
Talabostat mesylate: FAP, DPP4 & Assay Design
2026-08-13
Explore how Talabostat mesylate (PT-100) connects DPP4 and FAP inhibition with tumor microenvironment studies and better assay design. This article adds an epithelial-homeostasis perspective from NLRP10 research while clearly separating evidence, hypotheses, and practical limitations.
-
SAMe and Methylation in Neurological Disorders
2026-08-12
Bottiglieri, Hyland, and Reynolds present an integrative review linking ademetionine (S-adenosylmethionine; SAMe) metabolism with folate and vitamin B12 status, neurotransmitter regulation, and neurological disease. Its practical value lies in showing how biochemical methylation defects may connect diverse clinical phenotypes while emphasizing that therapeutic evidence for SAMe remained preliminary in several disorders.
-
Cap 1 OVA mRNA for Translational Immunology
2026-08-12
A mechanistic and strategic guide to using EZ Cap™ OVA mRNA as a controlled immune response immunogen, with practical insights on Cap 1 biology, delivery-system selection, experimental validation, and translational positioning.
-
KNUCKLES and Floral Meristem Termination
2026-08-11
This Arabidopsis study identifies KNUCKLES as an integrator of developmental repression, auxin distribution, and cytokinin activity during floral meristem termination. Its key advance is the demonstration that KNU directly represses PIN1 and IPT7 through H3K27me3-associated chromatin regulation, connecting hormone control with the WUS–CLV3 stem-cell network.
-
Nile Red Maps Lipid Vulnerability in Laryngeal Cancer
2026-08-11
Lipid metabolism is emerging as a clinically relevant dimension of laryngeal cancer biology. This thought-leadership article explains how Nile Red can translate THBS1-associated computational findings into spatial, cell-level lipid phenotyping while outlining the assay boundaries that matter for translational decisions.
-
Fenipentol Workflows for GI and Cardiometabolic Research
2026-08-10
Fenipentol, also called 1-Phenyl-1-pentanol, connects natural-product profiling with practical assays for secretion biology, ESR1-related signaling, and cardiometabolic research. This guide translates its discovery context into solvent handling, comparative tissue workflows, assay controls, and troubleshooting strategies.
-
G-1: Selective GPR30 Agonist Workflow Guide
2026-08-09
G-1 provides a focused way to activate GPR30/GPER1 while minimizing classical ERα and ERβ interference. This guide translates its calcium, PIP3, cancer-cell migration, and cardiovascular evidence into practical workflows with handling, controls, and troubleshooting guidance.
-
Allosteric PDK4 Inhibitors for Metabolic Disease
2026-08-08
The 2019 Journal of Medicinal Chemistry study identified anthraquinone-derived allosteric inhibitors of pyruvate dehydrogenase kinase 4, with compound 8c showing 84 nM biochemical potency and activity in metabolic, allergic, and cancer-related preclinical models. Its combination of medicinal chemistry, pharmacokinetic assessment, molecular docking, and animal testing provides a framework for studying PDH activation and disease-associated metabolic reprogramming.